Meet Vinay Prasad: The Progressive Leftist Saboteur Undermining President Trump’s FDA

In a stunning betrayal of President Donald Trump’s “Make America Healthy Again” vision, Dr. Vinay Prasad, a self-proclaimed progressive, has infiltrated the FDA’s leadership, securing a pivotal role as Director of the Center for Biologics Evaluation and Research (CBER) after being nominated for the role by HHS Secretary Robert F Kennedy, Jr. in May of 2025. Far from being the reformist ally the Trump administration expected he may be, Prasad’s liberal ideology, outspoken anti-Trump rhetoric, and deliberate actions to obstruct the President’s deregulatory agenda make him a dangerous misfit in this critical position. His continued presence at the FDA threatens to derail the Trump administration’s mission to streamline regulations and prioritize American health. The appointment of Vinay Prasad represents a catastrophic vetting failure that demands immediate action to protect Trump’s transformative healthcare agenda.

A Lifelong Progressive Liberal With An Anti-Trump Record

Vinay Prasad’s political alignment is unequivocally progressive, rooted in admiration for far-left figures like Elizabeth Warren and Bernie Sanders. His public statements and voting history reveal a deep-seated opposition to Trump and his policies, making his appointment to a key FDA role baffling. 

In 2021, Prasad described himself as a “political liberal, closest to Elizabeth Warren” and a “Sanders/Warren liberal,” proudly embracing a progressive identity. He voted for Bernie Sanders in the 2016 Democratic primary, and FEC records reveal he donated to Sanders’ campaign, signaling his support for radical left-wing policies.

In 2020, Prasad declared on X that he wanted “Biden to win more than anything” and confirmed he voted against Trump, solidifying his opposition to the President.

As recently as 2022 and 2023, Prasad reiterated his identity as a “lifelong progressive” and “Bernie fan,” leaving no doubt about his ideological leanings.

Prasad’s policy positions are a direct affront to the conservative principles underpinning Trump’s agenda. He advocates for universal basic income, student loan forgiveness, open borders, and Roe v. Wade abortion standards. He supports a 50% marginal tax rate for high earners, a wealth tax, single-payer healthcare, universally funded pre-K and community college, and expansive parental leave policies. 

On racial issues, he has called for economic remedies for “profound injustice towards the Black Community” and passionately defends affirmative action, decrying its banning as a “poisonous idea.” These positions are not mere differences of opinion—they are fundamentally at odds with the Trump administration’s priorities of limited government, anti-DEI, pro-deregulation, and economic freedom.

Prasad’s disdain for Trump is personal and vitriolic. He has called the President “perhaps the worst president in the history of the Republic” and claimed Trump disagreed with him “on probably 90% of issues.” He compared Trump’s family separation immigration policy to a “human rights violation” worthy of the International Criminal Court, mocked his election fraud claims as “laughable and pathetic,” and called January 6 “a terrible day.” Prasad even attacked Trump University as a “scam” and consistently refers to the President as “orange man,” a derogatory jab used by the radical Left to attack Trump over his tan skin. Prasad’s admiration for Dr. Anthony Fauci, whom he dubbed “St. Anthony of Fauci” with “profound reverence,” further highlights his alignment with figures Trump has criticized, particularly over the COVID-19 response.

Sabotaging Trump’s Deregulatory Agenda

Since assuming control of CBER at the FDA, Prasad has amassed unprecedented power, holding three key FDA roles: Chief Medical Officer, Chief Scientific Officer, and Director of CBER. Reports suggest he is under consideration to lead the Center for Drug Evaluation and Research (CDER), which could make him more influential than FDA Commissioner Marty Makary. This consolidation of authority in the hands of a Trump antagonist and avowed Leftist is a recipe for disaster, and Prasad’s actions demonstrate a clear intent to undermine President Trump’s vision. 

Defying Administration Directives

Upon beginning his second term, Trump issued a clear mandate to terminate remote work, yet Prasad emailed Center for Biologics Evaluation and Research (CBER) staff allowing telework up to two days per week, directly contradicting the administration’s return-to-office policy.

Stalling Deregulatory Reforms

Makary’s “plausible mechanism” pathway for rare diseases, a flagship initiative to accelerate drug approvals, has stalled under Prasad’s leadership. Analysts question whether his progressive views can align with Makary’s deregulatory approach, casting doubt on his commitment to Trump’s goals.

Missing Critical Deadlines

The FDA has missed multiple Prescription Drug User Fee Act (PDUFA) deadlines under Prasad, including GSK’s Nucala for COPD (May 7), and Stealth BioTherapeutics’ Barth syndrome treatment (April 29). More recently, Prasad has led arbitrary delays of gene and cell therapies from Ultragenyx and Capricor not based on science, but on his own left-wing agenda. These delays contradict Trump’s push for faster drug approvals, frustrating patients and industry alike.

A Regulatory Philosophy At Odds With Trump

Prasad’s regulatory philosophy is fundamentally anti-Trump. While the President has criticized the FDA’s “slow and burdensome” approval process, Prasad has argued for tougher reviews, dismissing Republican pressure to streamline approvals as misguided. He criticized Trump’s Right-To-Try policies, calling the President “incorrect” and blaming pharmaceutical companies, not the FDA, for delays in drug access. By publishing major policy changes in academic journals rather than through transparent public comment portals, Prasad has reduced opportunities for input from patients, providers, and industry, further eroding trust in the FDA.

 A Catastrophic Vetting Failure

Prasad’s appointment is a glaring intelligence and vetting failure. His nearly $4 million in funding from the left-leaning Arnold Foundation, residence in progressive strongholds like San Francisco and Oregon, and a history of making anti-Trump statements and support for the radical Left should have raised red flags. These issues, combined with his unabashed progressive activism, signal a profound misalignment with the Trump administration’s values. How someone with such a clear anti-Trump record was entrusted with a critical regulatory role at the FDA is a question that demands answers.

The Urgent Need for Prasad’s Removal From The FDA 

Vinay Prasad’s presence in the FDA is a betrayal of the voters who elected Trump to dismantle bureaucratic overreach and prioritize American health. His progressive ideology, personal attacks on the President, and actions—purging leadership, missing deadlines, defying directives, and overriding experts—prove he is not a reformist ally, but is unseated a saboteur. The Trump administration must act swiftly to remove him before he inflicts further damage on the “Make America Healthy Again” agenda. Allowing a trojan horse wield such power is a mistake that threatens the very reforms Trump was elected to deliver. The time to act is now—Prasad must go before he completely destroys the MAHA movement and all of the hard work President Trump has put into his regulatory reform agenda.

The post Meet Vinay Prasad: The Progressive Leftist Saboteur Undermining President Trump’s FDA appeared first on Loomered.